Although the Life Science sector is dominated by CSL, Cochlear, Symbion, Sigma and ResMed; there are 146 other companies in the sector, at various stages of development ranging from early stage drug discover to highly profitable ventures. The sector is valued at $32bn, but the excluding the top five entities; the sector is valued at $11bn.
Different companies require difference investment strategies, which is demonstrated by the fact that the Life Science sector has generated the highest returns over all other sectors over a 20 year period, yet this sector is also the most volatile. Intersuisse focuses on many of these companies at all levels of the business cycle, focusing on providing timely and accurate research for various types of investor.
